CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain management, today announced an agreement to expand its commercial supply relationship with Baxter Healthcare Corporation. The new supply agreement relates to Dyloject™, Javelin’s proprietary injectable diclofenac product currently marketed in the United Kingdom and in the second of two pivotal trials in the United States, for acute post-operative pain. The expanded relationship provides additional manufacturing capacity for Dyloject, principally for distribution in the European Union, and builds on the existing manufacturing agreement executed between Javelin and Baxter for the United States.
